Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion type Assertion NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_head.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion description "[Importantly, a related MCT1/2 inhibitor (AZD3965) is currently in phase I clinical trials in patients with advanced cancers: http://clinicaltrials.gov/show/NCT01791595.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_provenance.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion evidence source_evidence_literature NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_provenance.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion SIO_000772 25415228 NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_provenance.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion wasDerivedFrom befree-2016 NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_provenance.
- NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_assertion wasGeneratedBy ECO_0000203 NP1239104.RAyi5GaPKT-xrw63bBJx7VwECi6RAxhlhem-vaFdasu5w130_provenance.